Henry Ford Cancer Institute Receives Grant to Reduce Prostate Cancer Disparities Among Black Men Henry Ford Health System | Apr 21, 2021
Share this:
Henry Ford Cancer Institute has received a $250,000 grant from Pfizer Global Medical Grants and the American Cancer Society to reduce prostate cancer disparities among Black men. While all men are at risk for prostate cancer, Black men are at an increased risk for developing and dying from prostate cancer.
“Black men tend to develop prostate cancer at a younger age, have more advanced disease when diagnosed, and are twice as likely to die from prostate cancer versus men of other races and ethnicities,” said Eleanor M. Walker, M.D., director of Breast Radiation Oncology and medical director of Integrative Services at Henry Ford Cancer Institute. “These disparities are complex and multifactorial, with contributing factors that range from access to care, to genetics, environment, lifestyle and more. With the support
DBusiness Magazine
DBusiness Daily Update: State Grants $3.4M to Live Entertainment Venues, Henry Ford Cancer Institute to Increase Minority Participation in Clinical Trials, and More
Our roundup of the latest news from metro Detroit and Michigan businesses as well as announcements from government agencies, including updates about the COVID-19 pandemic. To share a business or nonprofit story, please send us a message.
Courtesy of Bridge
Our roundup of the latest news from metro Detroit and Michigan businesses as well as announcements from government agencies, including updates about the COVID-19 pandemic. To share a business or nonprofit story, please send us a message.
E-Mail
IMAGE: Eleanor M. Walker, M.D., PAACT co-investigator, and director of Breast Radiation Oncology and medical director of Integrative Services at Henry Ford view more
Credit: Henry Ford Health System
DETROIT (March 11, 2021) - Henry Ford Cancer Institute is launching the Participatory Action for Access to Clinical Trials (PAACT) project to dramatically improve the representation of the African American community and other minorities in cancer clinical trials.
Supported by a $750,000 grant from Genentech, PAACT is a community-based research initiative in collaboration with the Detroit Community-Academic Urban Research Center (Detroit URC) that will address various barriers to trust and participation in clinical trials. Researchers and community partners will focus on clinical trials involving breast, colorectal, lung, and prostate cancers, which are more likely to result in death for African Americans when compared to other racial and ethnic groups. The project
Henry Ford Cancer Institute launches new initiative to improve minority participation in clinical trials
Henry Ford Cancer Institute is launching the Participatory Action for Access to Clinical Trials (PAACT) project to dramatically improve the representation of the African American community and other minorities in cancer clinical trials.
Supported by a $750,000 grant from Genentech, PAACT is a community-based research initiative in collaboration with the Detroit Community-Academic Urban Research Center (Detroit URC) that will address various barriers to trust and participation in clinical trials. Researchers and community partners will focus on clinical trials involving breast, colorectal, lung, and prostate cancers, which are more likely to result in death for African Americans when compared to other racial and ethnic groups. The project is being implemented in partnership with community-based organizations and community leaders who are key stakeholders.
at Henry Ford Health System . “Through global collaboration, GBM AGILE is making it possible for some of the world’s foremost experts in glioblastoma research and treatment to collaborate and advance the pace at which scientific and clinical breakthroughs can be achieved.” After opening at Henry Ford Cancer Institute, the two new interventions –
VAL-083 from Kintara Therapeutics, Inc. and
paxalisib from Kazia Therapeutics Limited– will subsequently open at more than 35 trial sites across the United States, with additional global sites in Canada, Europe and China to follow.
VAL-083 is being evaluated in all three glioblastoma patient subtypes: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent.